Phase 1 (Preliminary safety and immunogenicity results)
Amp Volatility Score
Catalyst Info & Data Links
Title: COVID-19 Vaccine from Dynavax and Medicago Phase I Data
WHAT IS THE NEXT CATALYST EVENT?
Phase I Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
06-26-2018 (CpG 1018 technology for HBV) HEPLISAV-B®, 2-Dose Hepatitis B Vaccine Using a Toll-like Receptor 9 Adjuvant, is Well Tolerated and Induces Higher Rates of Seroprotection than Engerix-B in Persons with Diabetes Aged 60 Years or Older
08-2020 Corporate Overiew (slide 14)
05-2020 Dynavax Technologies Corporate Presentation (slides 12-13)
MECHANISM OF ACTION
CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell memory responses.
Adjuvants are a pharmacological or immunological substance that is combined with a specific protein (antigen) in a vaccine to help stimulate an immune response against the antigen. Some adjuvants work by stimulating specific immune pathways, such as toll like receptor 9 (TLR9), that promote stronger immune responses than with antigens alone.
Combining COVID-19 surface antigens with CpG 1018 for the vaccine to elicit a higher antibody titer.
Updated by MV
#COVID-19, #Dynavax, #CpG1018, #Coronavirus, #DVAX
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post